Date | Title | Description |
28.05.2025 | Hansa Biopharma's Strategic Restructuring: A Necessary Shift for Future Growth | In the world of biopharmaceuticals, change is the only constant. Hansa Biopharma, a pioneering company based in Lund, Sweden, is about to embark on a significant transformation. The company recently announced plans for a restructuring aimed... |
26.05.2025 | Hansa Biopharma plans restructuring to optimize resource allocation and improve operational efficiency | Hansa Biopharma plans restructuring to optimize resource allocation and improve operational efficiency
Mon, May 26, 2025 18:40 CET Report this content
Lund, Sweden, 26 May 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today an... |
26.05.2025 | Notice to Annual General Meeting in Hansa Biopharma AB (publ) | Notice to Annual General Meeting in Hansa Biopharma AB (publ)
Mon, May 26, 2025 07:00 CET Report this content
Lund, Sweden May 26, 2025, Hansa Biopharma AB (publ), Reg. No. 556734-5359 (“Hansa Biopharma”), with registered office in Lund, gi... |
15.05.2025 | A New Dawn for COPD Treatment: Dupixent's Approval in Singapore | In a significant breakthrough for chronic obstructive pulmonary disease (COPD) patients, Singapore has approved Dupixent (dupilumab) as the first biologic treatment for this debilitating condition. This decision, announced on May 14, 2025, ... |
14.05.2025 | Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS | Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS
Wed, May 14, 2025 08:00 CET Report this content
Lund, Sweden, 14 May 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA)... |
13.05.2025 | Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S. | Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.
Tue, May 13, 2025 08:00 CET Report this content
Lund, Sweden, 13 May 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced that Maria ... |
25.04.2025 | Hansa Biopharma: A New Era of Leadership and Growth | Hansa Biopharma is at a crossroads. The Swedish biopharmaceutical company has just reported its first-quarter financial results for 2025, showcasing a robust growth trajectory. With a new CEO at the helm, the company is poised for a transfo... |
24.04.2025 | Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results | Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results
Thu, Apr 24, 2025 08:00 CET Report this content
Strong product sales and key progress in pipeline catalysts
Lund, Sweden, 24 April 2025. Hansa Biopharma ... |
24.04.2025 | Hansa Biopharma appoints new Chief Executive Officer | Hansa Biopharma appoints new Chief Executive Officer
Thu, Apr 24, 2025 07:00 CET Report this content
Lund, Sweden, 24 April 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced the appointment of Renée Aguiar-Lucander ... |
03.04.2025 | Hansa Biopharma to host Q1 2025 interim results conference call | Hansa Biopharma to host Q1 2025 interim results conference call
Thu, Apr 03, 2025 08:00 CET Report this content
Lund, Sweden, 3 April, 2025. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January - Ma... |
25.03.2025 | Hansa Biopharma to attend Van Lanschot Kempen Life Sciences Conference | Hansa Biopharma to attend Van Lanschot Kempen Life Sciences Conference
Tue, Mar 25, 2025 09:00 CET Report this content
Lund, Sweden, 25 March 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced it will attend Van Lans... |
21.03.2025 | Hansa Biopharma publishes 2024 Annual and Sustainability Reports | Hansa Biopharma publishes 2024 Annual and Sustainability Reports
Fri, Mar 21, 2025 15:00 CET Report this content
Lund, Sweden, 21 March 2025. Hansa Biopharma AB, “Hansa” or the “Company” (Nasdaq Stockholm: HNSA), today published its Annual ... |
14.03.2025 | Hansa Biopharma's Breakthrough in Kidney Transplantation: A New Hope for Highly Sensitized Patients | In the world of medicine, breakthroughs often feel like a distant star—visible, yet unreachable. However, Hansa Biopharma is changing that narrative for highly sensitized kidney transplant patients. The company recently announced the comple... |
11.03.2025 | Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients | Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients
Tue, Mar 11, 2025 14:35 CET Report this content
Lund, Sweden, 11 March 2025.... |
04.03.2025 | Hansa Biopharma to attend Leerink Partners Global Healthcare Conference | Hansa Biopharma to attend Leerink Partners Global Healthcare Conference
Tue, Mar 04, 2025 08:00 CET Report this content
Lund, Sweden, 4 March 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced it will attend Leerink ... |
24.02.2025 | Hansa Biopharma to attend TD Cowen Healthcare Conference | Hansa Biopharma to attend TD Cowen Healthcare Conference
Mon, Feb 24, 2025 08:00 CET Report this content
Lund, Sweden, 24 February 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced it will attend TD Cowen's 45th Ann... |
06.02.2025 | Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results | Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results
Thu, Feb 06, 2025 07:00 CET Report this content
IDEFIRIX Product Sales Increased 83% Compared to the Prior Year
Lund, Sweden, February 6, 2025, Hansa Biopharma AB, ... |
23.01.2025 | Hansa Biopharma to host Year-end report 2024 conference call | Hansa Biopharma to host Year-end report 2024 conference call
Thu, Jan 23, 2025 07:00 CET Report this content
Lund, Sweden, January 23, 2025. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its year-end report for January-Dec... |
07.01.2025 | Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference | Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
Tue, Jan 07, 2025 16:45 CET Report this content
Lund, Sweden, 7 January 2025. Hansa Biopharma AB, “Hansa" or the "Company” (Nasdaq Stockholm: HNSA), today announced ... |
20.12.2024 | New Frontiers in Obesity Treatment: ASC47 and Imlifidase Show Promise | In the battle against obesity and autoimmune diseases, two recent studies shine a light on innovative treatments that could change the landscape of medical care. Ascletis Pharma's ASC47 and Hansa Biopharma's imlifidase are making waves, eac... |
17.12.2024 | Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome | Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome
Tue, Dec 17, 2024 21:40 CET Report this content
Lund, Sweden, 17 December 2024... |
11.12.2024 | Syntara and Hansa Biopharma: Pioneering Hope in Rare Diseases | In the realm of biopharmaceuticals, two companies are making waves with promising clinical trials that could reshape treatment landscapes for rare diseases. Syntara Limited and Hansa Biopharma are at the forefront, each with a unique approa... |
05.12.2024 | Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease | Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease
Thu, Dec 05, 2024 15:30 CET Report this content
Data from the trial is expected to be shared in 2025
Lund, Sweden... |
03.12.2024 | Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome | Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
Tue, Dec 03, 2024 07:00 CET Report this content
The trial will be conducted in patients with ... |
13.11.2024 | Hansa Biopharma to Attend Jefferies London Healthcare Conference | Hansa Biopharma to Attend Jefferies London Healthcare Conference
Wed, Nov 13, 2024 09:00 CET Report this content
Lund, Sweden, 13 November, 2024. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA) today announced it will attend Jefferies Lon... |
30.10.2024 | Hansa Biopharma to Attend Truist Securities BioPharma Symposium | Hansa Biopharma to Attend Truist Securities BioPharma Symposium
Wed, Oct 30, 2024 09:00 CET Report this content
Lund, Sweden, 30 October, 2024. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA) today announced it will attend Truist Securiti... |
17.10.2024 | Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results | Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results
Thu, Oct 17, 2024 07:00 CET Report this content
Q3 2024 marks highest ever in-market quarterly sales performance and fourth consecutive quarter of ... |
08.10.2024 | Hansa Biopharma's Breakthrough in Autoimmune Treatment: A New Hope for Patients | In the realm of biopharmaceuticals, innovation is the lifeblood. Hansa Biopharma, a pioneering company based in Lund, Sweden, is making waves with its latest development: HNSA-5487. This next-generation immunoglobulin G (IgG)-cleaving enzym... |
07.10.2024 | Hansa Biopharma’s HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial | Hansa Biopharma’s HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial
Mon, Oct 07, 2024 10:00 CET Report this content
Lund, Sweden, 7 October 2024. Hansa Biopharma A... |
03.10.2024 | Hansa Biopharma to host Q3 2024 interim results conference call | Hansa Biopharma to host Q3 2024 interim results conference call
Thu, Oct 03, 2024 07:00 CET Report this content
Lund, Sweden, October 3, 2024. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January-Se... |
05.09.2024 | Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference | Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Thu, Sep 05, 2024 11:00 CET Report this content
Lund, September 5, 2024. Hansa Biopharma today announced that Søren Tulstrup will participate in a Fi... |
23.08.2024 | Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis | Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis
Fri, Aug 23, 2024 18:00 CET Report this content
Lund, Sweden, 23 August 2024. Hansa Biopharma AB, (“Hansa” or the “Company”) (Nasdaq Stockholm: HNSA), today an... |
18.07.2024 | Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update | Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update
Thu, Jul 18, 2024 07:00 CET Report this content
Lund, Sweden, July 18, 2024, Hansa Biopharma today announced its first half and second quarter 2024 financial ... |
03.07.2024 | Hansa Biopharma to host Q2 2024 interim results conference call | Hansa Biopharma to host Q2 2024 interim results conference call
Wed, Jul 03, 2024 07:00 CET Report this content
Lund, Sweden, July 3, 2024. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January-June ... |
28.06.2024 | Hansa Biopharma: increase in number of shares and votes | Hansa Biopharma: increase in number of shares and votes
Fri, Jun 28, 2024 07:00 CET Report this content
Lund, Sweden June 28, 2024. Hansa Biopharma AB, (“Hansa Biopharma” or the “Company”) (Nasdaq Stockholm: HNSA) today announced that Hansa... |
27.06.2024 | Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ) | Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
Thu, Jun 27, 2024 15:00 CET Report this content
Lund, Sweden, June 27, 2024. Hansa Biopharma AB (publ), “Hansa” (Nasdaq Stockholm: HNSA), has today on June 27, 2024 held ... |
07.06.2024 | Hansa Biopharma publishes prospectus for admission to trading of shares on Nasdaq Stockholm | Hansa Biopharma publishes prospectus for admission to trading of shares on Nasdaq Stockholm
Fri, Jun 07, 2024 09:15 CET Report this content
Lund, Sweden June 7, 2024. Hansa Biopharma AB, (“Hansa” or the “Company”) (Nasdaq Stockholm: HNSA) o... |
31.05.2024 | Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial | Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial
Fri, May 31, 2024 13:30 CET Report this content
Lund, Sweden, 31 May, 2024. Hansa Biopharma AB, (“Hansa” or the “Company”) (Nasdaq Stockholm: HNSA), today announce... |
27.05.2024 | Notice to Annual General Meeting in Hansa Biopharma AB (publ) | Notice to Annual General Meeting in Hansa Biopharma AB (publ)
Mon, May 27, 2024 10:00 CET Report this content
Lund, Sweden May 27, 2024, Hansa Biopharma AB (publ), Reg. No. 556734-5359 (“Hansa Biopharma”), with registered office in Lund, gi... |
21.05.2024 | Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting | Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting
Tue, May 21, 2024 07:00 CET Report this content
Lund, Sweden, 21 May, 2024. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), today announced data featurin... |
03.05.2024 | Hansa Biopharma: increase in number of shares and votes | Hansa Biopharma: increase in number of shares and votes
Fri, May 03, 2024 08:00 CET Report this content
Lund, Sweden May 3, 2024. Hansa Biopharma AB (publ), (“Hansa” or the “Company”) (Nasdaq Stockholm: HNSA) today announced that the compan... |
03.05.2024 | Correction: Hansa Biopharma: increase in number of shares and votes | Correction: Hansa Biopharma: increase in number of shares and votes
Fri, May 03, 2024 11:11 CET Report this content
The correction only concerns the removal of the reference to the EU Market Abuse Regulation that was incorrectly included in... |
18.04.2024 | Hansa Biopharma interim report January-March 2024 | Hansa Biopharma interim report January-March 2024
Thu, Apr 18, 2024 07:00 CET Report this content
• Strong sales performance and solid momentum with the Phase 3 trial in anti-GBM disease
• Cash runway extended into 2026
• Evan Ballantyne jo... |
02.04.2024 | Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance | Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
Tue, Apr 02, 2024 07:00 CET Report this content
Company expects revenue of SEK 54m including product sales of SEK 48m - an increase of 10% versus the prior quarter and a 23... |
21.03.2024 | Hansa Biopharma publishes 2023 Annual and Sustainability Reports | Hansa Biopharma publishes 2023 Annual and Sustainability Reports
Thu, Mar 21, 2024 07:00 CET Report this content
Company delivered significant progress across commercial and R&D priorities
Lund, Sweden, March 21, 2024. Hansa Biopharma A... |
22.02.2024 | Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer | Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer
Thu, Feb 22, 2024 15:00 CET Report this content
Lund, Sweden, 22 February 2024. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), today announced the appointment of Evan Ba... |
02.02.2024 | Hansa Biopharma Year-end report January-December 2023 | Hansa Biopharma Year-end report January-December 2023
Fri, Feb 02, 2024 07:00 CET Report this content
Strong revenue generation in Q4 2023 including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany... |
06.01.2024 | Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference | Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
Sat, Jan 06, 2024 14:00 CET Report this content
Strong revenue generation in Q4 2023, including SEK 43m in Idefirix® product sales s... |
14.12.2023 | Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation | Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation
Thu, Dec 14, 2023 20:00 CET Report this content
Statistically significant reduction in donor-specific antibodies (DSAs) ob... |
13.12.2023 | Hansa Biopharma Nomination Committee formed | Hansa Biopharma Nomination Committee formed
Wed, Dec 13, 2023 07:00 CET Report this content
Lund, December 13, 2023. Hansa Biopharma today announced that the Nomination Committee has been formed in accordance with the principles adopted by ... |
07.12.2023 | Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS) | Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)
Thu, Dec 07, 2023 07:00 CET Report this content
Lund, Sweden, 7 December 2023. Hansa Biophar... |
05.12.2023 | Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables | Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables
Tue, Dec 05, 2023 13:05 CET Report this content
Lund, Sweden, 5 December 2023. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), annou... |
27.11.2023 | Hansa Biopharma announces planned departure of Chief Financial Officer Donato Spota | Hansa Biopharma announces planned departure of Chief Financial Officer Donato Spota
Mon, Nov 27, 2023 07:00 CET Report this content
Lund, Sweden, 27 November 2023. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme techn... |
26.10.2023 | Hansa Biopharma Interim Report January-September 2023 | Hansa Biopharma Interim Report January-September 2023
Thu, Oct 26, 2023 07:00 CET Report this content
• Encouraging high-level results for first-in-human trial of HNSA-5487
• Well attended Hansa-sponsored symposium at ESOT focusing on first... |
17.10.2023 | Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study | Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study
Tue, Oct 17, 2023 07:00 CET Report this content
Lund, Sweden, 17 October 2023. Hansa Biopharma... |
11.10.2023 | Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients | Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients
Wed, Oct 11, 2023 18:35 CET Report this content
Biologic License Application submission expected for 2025
Lund, Sweden, 11 October, 2023. Hansa B... |
09.10.2023 | Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487 | Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487
Mon, Oct 09, 2023 17:35 CET Report this content
HNSA-5487 is a next-generation IgG-cleaving enzyme and the lead candidate in the NiceR developmen... |
01.09.2023 | Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma | Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma
Fri, Sep 01, 2023 12:00 CET Report this content
Lund, Sweden, 1 September 2023. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for r... |
31.07.2023 | Hansa Biopharma: Increase of the number of votes | Hansa Biopharma: Increase of the number of votes
Mon, Jul 31, 2023 08:00 CET Report this content
Lund, Sweden, July 31, 2023. Hansa Biopharma AB “Hansa” or the “Company”, (Nasdaq Stockholm: HNSA), the pioneer enzyme technology for rare immu... |
20.07.2023 | Hansa Biopharma half year report 2023 | Hansa Biopharma half year report 2023
Thu, Jul 20, 2023 07:00 CET Report this content
Solid product sales in Q2 2023
Collaboration announced in gene therapy with Genethon in Crigler-Najjar syndrome
New Eurotransplant desensitization program... |
06.07.2023 | Hansa Biopharma to host conference call to provide half year results for January-June 2023 and a Business Update | Hansa Biopharma to host conference call to provide half year results for January-June 2023 and a Business Update
Thu, Jul 06, 2023 08:00 CET Report this content
Lund, Sweden, July 6, 2023 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will pub... |
04.07.2023 | Hansa Biopharma AB recognizes a write-up of SEK 1.430 billion in intangible assets related to Idefirix in the financial statements of the parent company - no impact on the consolidated financials | Hansa Biopharma AB recognizes a write-up of SEK 1.430 billion in intangible assets related to Idefirix in the financial statements of the parent company - no impact on the consolidated financials
Tue, Jul 04, 2023 12:05 CET Report this cont... |
29.06.2023 | Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ) | Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
Thu, Jun 29, 2023 17:00 CET Report this content
Lund, Sweden, June 29, 2023. Hansa Biopharma AB (publ), “Hansa” (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for... |
30.05.2023 | Hansa announces first patient dosed with imlifidase in a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease | Hansa announces first patient dosed with imlifidase in a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease
Tue, May 30, 2023 08:00 CET Report this content
Lund, Sweden May 30, 2023. Hansa Biopharma (“Hansa... |
29.05.2023 | Notice to Annual General Meeting in Hansa Biopharma AB (publ) | Notice to Annual General Meeting in Hansa Biopharma AB (publ)
Mon, May 29, 2023 16:00 CET Report this content
Lund, Sweden May 29, 2023, Hansa Biopharma AB (publ), Reg. No. 556734-5359 (“Hansa Biopharma”), with registered office in Lund, gi... |
27.04.2023 | Hansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies | Hansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies
Thu, Apr 27, 2023 17:30 CET Report this content
Lund, Sweden and Evry, F... |
20.04.2023 | Hansa Biopharma interim report January–March 2023 | Hansa Biopharma interim report January–March 2023
Thu, Apr 20, 2023 08:00 CET Report this content
Positive reimbursement decision in Spain expands market access to include the five largest European markets
Enrollment in phase 2 study of iml... |
14.04.2023 | Hansa Biopharma to host conference call to provide interim results for January-March 2023 and a Business Update | Hansa Biopharma to host conference call to provide interim results for January-March 2023 and a Business Update
Fri, Apr 14, 2023 08:00 CET Report this content
Lund, Sweden, April 14, 2023 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will pu... |
31.03.2023 | Hansa Biopharma completes enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) | Hansa Biopharma completes enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS)
Fri, Mar 31, 2023 08:00 CET Report this content
Lund, Sweden, 31 March 2023. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer i... |
30.03.2023 | Hansa Biopharma publishes Annual Report 2022 | Hansa Biopharma publishes Annual Report 2022
Thu, Mar 30, 2023 08:00 CET Report this content
Lund, Sweden, March 30, 2023 Hansa Biopharma AB “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions,... |
29.03.2023 | Hansa Biopharma announces positive reimbursement decision in Spain for Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation | Hansa Biopharma announces positive reimbursement decision in Spain for Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation
Wed, Mar 29, 2023 15:00 CET Report this content
Lund, Swed... |
03.03.2023 | Matthew Shaulis appointed Chief Commercial Officer and US President of Hansa Biopharma | Matthew Shaulis appointed Chief Commercial Officer and US President of Hansa Biopharma
Fri, Mar 03, 2023 07:30 CET Report this content
Lund, Sweden, 3 March 2023. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme techno... |
02.02.2023 | Hansa Biopharma Year-end report January-December 2022 | Total 2022 revenue of SEK 155m Cash runway extended into 2025 Market Access obtained in four of the five largest European markets Reported positive Phase 2 top-line data in AMR Decision made to initiate clinical study with imlifidase as a p... |
02.02.2023 | Hansa Biopharma Year-end report January-December 2022 | Hansa Biopharma Year-end report January-December 2022
Thu, Feb 02, 2023 08:00 CET Report this content
Total 2022 revenue of SEK 155m
Cash runway extended into 2025
Market Access obtained in four of the five largest European markets
Reported... |
30.01.2023 | Hansa Biopharma announces planned departure of Chief Scientific Officer Christian Kjellman | Hansa Biopharma announces planned departure of Chief Scientific Officer Christian Kjellman
Mon, Jan 30, 2023 17:00 CET Report this content
Christian Kjellman also served as Chief Operating Officer since January 2020
Lund, Sweden, 30 January... |
20.01.2023 | Hansa Biopharma to host conference call to provide Year-end 2022 results and a Business Update | Hansa Biopharma to host conference call to provide Year-end 2022 results and a Business Update
Fri, Jan 20, 2023 08:00 CET Report this content
Lund, Sweden, January 20, 2023 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its Year-... |
02.01.2023 | Hansa Biopharma announces positive reimbursement decision for Idefirix® (imlifidase) in the Czech Republic | Idefirix® is the first and only product approved for use in highly sensitized patients waiting for a kidney transplant in the Czech Republic1,2 Availability of Idefirix® for eligible highly sensitized patients to begin January 1, 2023
LUND,... |
30.12.2022 | Hansa Biopharma: Increase of the number of shares and votes | LUND, Sweden, Dec. 30, 2022 /PRNewswire/ -- Hansa Biopharma AB "Hansa" or the "Company", (NASDAQ Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announces that the Company's regi... |
30.12.2022 | Hansa Biopharma: Increase of the number of shares and votes | Hansa Biopharma: Increase of the number of shares and votes
Fri, Dec 30, 2022 08:00 CET Report this content
Lund, Sweden, December 30, 2022. Hansa Biopharma AB “Hansa” or the “Company”, (Nasdaq Stockholm: HNSA), a pioneer in enzyme technolo... |
28.12.2022 | Correction: Hansa Biopharma Nomination Committee formed | Correction: Hansa Biopharma Nomination Committee formed
Wed, Dec 28, 2022 18:00 CET Report this content
The correction only concerns the removal of the reference to the EU Market Abuse Regulation that was incorrectly included in the origina... |
23.12.2022 | Hansa Biopharma Nomination Committee formed | Hansa Biopharma Nomination Committee formed
Fri, Dec 23, 2022 08:00 CET Report this content
Lund, December 23, 2022. Hansa Biopharma today announced that the Nomination Committee has been formed in accordance with the principles adopted by ... |
02.11.2022 | Hansa Biopharma and partner Sarepta Therapeutics plan to initiate a clinical study with imlifidase as a pre-treatment to Sarepta’s SRP-9001 gene therapy in DMD in 2023 | Hansa Biopharma and partner Sarepta Therapeutics plan to initiate a clinical study with imlifidase as a pre-treatment to Sarepta’s SRP-9001 gene therapy in DMD in 2023
Wed, Nov 02, 2022 21:30 CET Report this content The clinical study will ... |
31.10.2022 | Hansa Biopharma: Increase of the number of shares and votes | Hansa Biopharma: Increase of the number of shares and votes
Mon, Oct 31, 2022 17:00 CET Report this content
Lund, Sweden, October 31, 2022. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immuno... |
12.09.2022 | The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma’s Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients | The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma’s Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
Mon, Sep 12, 2022 15:30 CET Report this content Idefirix® bec... |
09.09.2022 | Hansa Biopharma: Issue and repurchase of class C shares for incentive programs | Hansa Biopharma: Issue and repurchase of class C shares for incentive programs
Fri, Sep 09, 2022 19:00 CET Report this content
Lund September 9, 2022. The board of directors for Hansa Biopharma AB (publ) has today resolved to issue 850,769 ... |
22.08.2022 | Hansa Biopharma and Medison Pharma announce positive reimbursement decision in Poland for Idefirix® in highly sensitized kidney transplant patients | Hansa Biopharma and Medison Pharma announce positive reimbursement decision in Poland for Idefirix® in highly sensitized kidney transplant patients
Mon, Aug 22, 2022 14:00 CET Report this content
Idefirix® (imlifidase) becomes the first and... |
10.08.2022 | European Society for Organ Transplantation’s (ESOT) guidelines for desensitization treatment of highly sensitized kidney transplant patients published in Transplant International | European Society for Organ Transplantation’s (ESOT) guidelines for desensitization treatment of highly sensitized kidney transplant patients published in Transplant International
Wed, Aug 10, 2022 08:00 CET Report this content
European guid... |
19.07.2022 | Hansa Biopharma half year report 2022 | Hansa Biopharma half year report 2022
Tue, Jul 19, 2022 08:00 CET Report this content
• Continued solid sales in Q2
• Positive NICE recommendation obtained
• Completed enrollment in imlifidase Phase 2 program in AMR
• Peter Nicklin elected ... |
18.07.2022 | Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company’s antibody-cleaving enzyme technology platform | Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company’s antibody-cleaving enzyme technology platform
Mon, Jul 18, 2022 21:00 CET Report this content
Pro... |
11.07.2022 | Hansa Biopharma announces first patient treated in the post-authorization efficacy study (PAES) of Idefirix® (imlifidase) in highly sensitized kidney transplant patients | Hansa Biopharma announces first patient treated in the post-authorization efficacy study (PAES) of Idefirix® (imlifidase) in highly sensitized kidney transplant patients
Mon, Jul 11, 2022 08:00 CET Report this content The PAES is an open-la... |
30.06.2022 | Hansa Biopharma to host conference call to provide half year results for January-June 2022 and Business Update | Hansa Biopharma to host conference call to provide half year results for January-June 2022 and Business Update
Thu, Jun 30, 2022 08:00 CET Report this content
Lund, Sweden June 30, 2022 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publi... |
30.06.2022 | Increase of the number of votes in Hansa Biopharma | Increase of the number of votes in Hansa Biopharma
Thu, Jun 30, 2022 17:35 CET Report this content
Lund, Sweden, June 30, 2022. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological condit... |
30.06.2022 | Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ) | Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
Thu, Jun 30, 2022 12:30 CET Report this content
Lund, Sweden, June 30, 2022. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare i... |
16.06.2022 | NICE recommends use of Hansa Biopharma’s Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients | NICE recommends use of Hansa Biopharma’s Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
Thu, Jun 16, 2022 07:00 CET Report this content Idefirix® becomes the first and only product recom... |
30.05.2022 | The Nomination Committee in Hansa Biopharma proposes Peter Nicklin as new chair of the Board of Directors at the Annual General Meeting 2022 | The Nomination Committee in Hansa Biopharma proposes Peter Nicklin as new chair of the Board of Directors at the Annual General Meeting 2022
Mon, May 30, 2022 15:55 CET Report this content
The Nomination Committee in Hansa Biopharma has com... |
30.05.2022 | Hansa Biopharma: Notice to Annual General Meeting | Hansa Biopharma: Notice to Annual General Meeting
Mon, May 30, 2022 16:00 CET Report this content
Lund, Sweden May 30, 2022, Hansa Biopharma AB (publ), Reg. No. 556734-5359 (“Hansa Biopharma”), with registered office in Lund, gives notice t... |
23.05.2022 | Hansa Biopharma completes enrollment in imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation | Hansa Biopharma completes enrollment in imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation
Mon, May 23, 2022 08:00 CET Report this content
30 patients with active or chronic active antibody me... |
13.05.2022 | Hansa Biopharma announces temporary marketing authorization in Switzerland for Idefirix[®] (imlifidase) in kidney transplantation | Hansa Biopharma announces temporary marketing authorization in Switzerland for Idefirix[®] (imlifidase) in kidney transplantation
Fri, May 13, 2022 08:00 CET Report this content
Approval by Swissmedic1 enables highly sensitized patients in ... |
21.04.2022 | Hansa Biopharma interim report January – March 2022 | Hansa Biopharma interim report January – March 2022
Thu, Apr 21, 2022 08:00 CET Report this content
Solid sales growth in Q1 2022
Market access secured in Germany and in France
Marketing authorization granted in Israel
Results from Phase 2 ... |
20.04.2022 | Hansa Biopharma granted added benefit ASMR 3 by French Transparency Commission for Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients | Hansa Biopharma granted added benefit ASMR 3 by French Transparency Commission for Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
Wed, Apr 20, 2022 18:00 CET Report this content Idefirix... |